Novacyt (LON:NCYT) Hits New 12-Month Low – Here’s What Happened

Shares of Novacyt S.A. (LON:NCYT) reached a new 52-week low during trading on Monday . The company traded as low as GBX 35.28 and last traded at GBX 35.28, with a volume of 14185 shares traded. The stock had previously closed at GBX 36.60.

Novacyt Stock Performance

The stock has a market capitalization of £24.92 million, a price-to-earnings ratio of -0.82 and a beta of -1.86. The company’s fifty day simple moving average is GBX 38.67 and its 200 day simple moving average is GBX 40.01. The company has a quick ratio of 4.46, a current ratio of 4.04 and a debt-to-equity ratio of 1.92.

Novacyt (LON:NCYT) last announced its earnings results on Tuesday, September 30th. The company reported GBX (0.10) EPS for the quarter. Novacyt had a negative return on equity of 47.73% and a negative net margin of 203.06%.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.